Tocqueville Asset Management L.P. Cidara Therapeutics, Inc. Transaction History

Tocqueville Asset Management L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$0.64 - $0.92 $43,520 - $62,560	68,000 Added 71.58%	163,000 $149,000
Q4 2023 Feb 12, 2024	SELL	$0.68 - $0.97 $2,040 - $2,910	-3,000 Reduced 3.06%	95,000 $75,000
Q3 2023 Nov 09, 2023	SELL	$0.77 - $1.16 $11,550 - $17,400	-15,000 Reduced 13.27%	98,000 $92,000
Q2 2023 Aug 11, 2023	SELL	$1.01 - $1.42 $54,540 - $76,680	-54,000 Reduced 32.34%	113,000 $127,000
Q1 2023 May 10, 2023	BUY	$0.75 - $1.98 $23,250 - $61,380	31,000 Added 22.79%	167,000 $212,000
Q4 2022 Feb 09, 2023	BUY	$0.48 - $13.08 $15,360 - $418,560	32,000 Added 30.77%	136,000 $103,000
Q3 2022 Nov 10, 2022	BUY	$0.45 - $13.0 $46,800 - $1.35 Million	104,000 New	104,000 $65,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.43B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.